Neuro-oncology最新文献

{"title":"Characterizing long-term neurocognitive outcomes through diffusion tensor imaging in childhood brain tumor survivors.","authors":"Ryan T Oglesby, Chathurangi H Pathiravasan, Elizabeth Olatunji, Leslie Chang, Jill Chotiyanonta, Yuto Uchida, Junghoon Lee, Kenichi Oishi, Rachel K Peterson, Sahaja Acharya","doi":"10.1093/neuonc/noaf083","DOIUrl":"10.1093/neuonc/noaf083","url":null,"abstract":"<p><strong>Background: </strong>Diffusion tensor imaging (DTI) can probe the longitudinal microstructural integrity and development of the brain. This study characterizes the relationship between long-term neurocognition and changes in fractional anisotropy (FA) and mean diffusivity (MD) of the corpus callosum and hippocampus in childhood brain tumor survivors.</p><p><strong>Methods: </strong>Patients diagnosed with a brain tumor at <18 years of age with ≥2 neurocognitive assessments retrospectively paired with DTI were eligible. Multitrajectory modeling clustered patients into distinct neurocognitive trajectories based on intelligent quotient, Processing Speed Index and working memory. Linear mixed models were used to determine whether patient clusters were associated with change in MD and FA. Patient clusters were compared to healthy subjects.</p><p><strong>Results: </strong>From 2014 to 2022, 68 patients with 464 neurocognitive assessments paired with DTI and 80 healthy subjects were included. Multitrajectory modeling identified two patient clusters: (1) low-performance, with declining scores below the normative mean, and (2) normal performance. Compared to the low-performance group, the normal-performance group demonstrated greater increase in FA and greater decrease in MD within the corpus callosum and hippocampus, respectively. This pattern was consistent across multiple white matter tracts, highlighting global differences between the groups. Directional change of FA and MD observed in healthy subjects mirrored that of the normal-performance group, but was opposite to that of the low-performance group.</p><p><strong>Conclusion: </strong>Compared to the normal-performance group, the low-performance group demonstrated reduced white matter microstructural integrity and higher mean diffusivity in the hippocampus over time, opposite to what is observed in normally developing children. This suggests aberrant neurodevelopment may contribute to late-neurocognitive impairment.</p>","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":"2182-2193"},"PeriodicalIF":13.4,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12448841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143677067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic profiling of meningioma reveals novel subgroup-specific biologic insights and outcome dependencies.","authors":"Alexander P Landry, Justin Z Wang, Leeor S Yefet, Jeff Liu, Vikas Patil, Wen-Jiang Zhang, Julio Sosa, Yosef Ellenbogen, Chloe Gui, Andrew Ajisebutu, Kenneth Aldape, Andrew Gao, Thomas Kislinger, Eric X Chen, Farshad Nassiri, Gelareh Zadeh","doi":"10.1093/neuonc/noae281","DOIUrl":"10.1093/neuonc/noae281","url":null,"abstract":"<p><strong>Background: </strong>Our group and others have recently identified four molecular groups of meningioma, with unique underlying biology and outcomes. The relevance of group-specific metabolite profiles (particularly among hypermetabolic tumors), has not been explored.</p><p><strong>Methods: </strong>We performed untargeted metabolic profiling of meningiomas representing each molecular group and World Health Organization (WHO) grade. Prognostic biochemicals were identified using Cox regression and their biological importance was explored using RNA and protein-based pathway analyses. Validation was performed using targeted high performance liquid chromatography-mass spectrometry (HPLC-MS/MS).</p><p><strong>Results: </strong>Global metabolic profiling identified 560 unique biochemicals. We identified a 21-metabolite outcome signature which is strongly predictive of outcome after adjusting for WHO grade, extent of resection, and receipt of adjuvant radiotherapy (HR = 326.49, 95% CI = 16.72-6375.48, P < .0001). The abundance of N6-trimethyllysine was associated with earlier time to recurrence on our whole cohort (log-rank P = .009) and within hypermetabolic and WHO grade 2 tumors specifically; this was validated using targeted HPLC-MS/MS on two cohorts. Consensus RNA and protein expression analysis demonstrated as association between N6-trimethyllysine abundance and activation of oxidative phosphorylation pathways, which portended worse outcomes in the hypermetabolic subgroup but, interestingly, better outcomes in the proliferative subgroup. By contrast, upregulated pyruvate and lactate transporters were associated with worse outcomes in proliferative meningiomas specifically.</p><p><strong>Conclusions: </strong>This is the first study to demonstrate a subgroup-specific prognostic role of N6-trimethyllysine in hypermetabolic meningiomas, offering increasingly granular outcome predictions using a widely accessible technique (HPLC-MS/MS). We also suggest fundamental differences in preferred energy utilization between and a potential need for subgroup-specific therapies.</p>","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":"2047-2059"},"PeriodicalIF":13.4,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12448868/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143033749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TUXEDO-3: A phase 2 trial of patritumab deruxtecan for patients with leptomeningeal metastasis.","authors":"Emilie Le Rhun, Enrico Franceschi, Michael Weller","doi":"10.1093/neuonc/noaf122","DOIUrl":"10.1093/neuonc/noaf122","url":null,"abstract":"","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":"1927-1929"},"PeriodicalIF":13.4,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12448835/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144216422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spatially resolved transcriptomics of benign and malignant peripheral nerve sheath tumors.","authors":"Juliane Bremer, Pamela Franco, Joelle Aline Menstell, Shelisa Tey, Kamil Kajetan Zajt, Klimentina Popzhelyazkova, Kay Nolte, Jürgen Schlegel, Maria Teresa Pedro, Anja Osterloh, Daniel Delev, Marc Hohenhaus, Christoph Scholz, Oliver Schnell, Juergen Beck, Joachim Weis, Dieter Henrik Heiland","doi":"10.1093/neuonc/noaf016","DOIUrl":"10.1093/neuonc/noaf016","url":null,"abstract":"<p><strong>Background: </strong>Peripheral nerve sheath tumors (PNSTs) encompass entities with different cellular differentiation and degrees of malignancy. Spatial heterogeneity complicates the diagnosis and grading of PNSTs in some cases. In malignant PNST (MPNST) for example, single-cell sequencing data has shown dissimilar differentiation states of tumor cells. Here, we aimed to determine the spatial and biological heterogeneity of PNSTs.</p><p><strong>Methods: </strong>We performed spatial transcriptomics on formalin-fixed paraffin-embedded diseased peripheral nerve tissue. We used spatial clustering and weighted correlation network analysis to construct niche-similarity networks and gene expression modules. We determined differential expression in primary pathologies, analyzed pathways to investigate the biological significance of identified meta-signatures, integrated the transcriptional data with histological features and existing single-cell data, and validated expression data by immunohistochemistry.</p><p><strong>Results: </strong>We identified distinct transcriptional signatures differentiating PNSTs. Immune cell infiltration, APOD, and perineurial fibroblast marker expression highlighted the neurofibroma component of hybrid PNSTs (HPNSTs). While APOD was evenly expressed in neurofibromatous tumor tissue in both, HPNST and pure neurofibromas, perineurial fibroblast markers were evenly expressed in HPNST, but restricted to the periphery in plexiform neurofibromas. Furthermore, we provide a spatial cellular differentiation map for MPNST, locating Schwann cell precursor and neural crest-like cells as well as those with mesenchymal transition.</p><p><strong>Conclusions: </strong>This pilot study shows that applying spatial transcriptomics to PNSTs provides important insight into their biology. It helps establish new markers and provides spatial information about the cellular composition and distribution of cellular differentiation states. By integrating morphological and high-dimensional molecular data it can improve PNSTs classification in the future.</p>","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":"2073-2087"},"PeriodicalIF":13.4,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12448819/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143024237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EANS-EANO Guidelines on the extent of resection in gliomas.","authors":"Roland Goldbrunner, Nicolas Foroglou, Francesco Signorelli, Philippe Schucht, Asgeir S Jakola, Giuseppe Minniti, Radoslaw Rola, Mirjam Renovanz, Matthias Preusser, Julia Furtner, Rachel Grossman, Christian Mawrin, Andreas Demetriades, Michael Weller, Matthias Simon","doi":"10.1093/neuonc/noaf217","DOIUrl":"https://doi.org/10.1093/neuonc/noaf217","url":null,"abstract":"<p><p>Intense efforts are employed to optimize neurosurgical resection of gliomas in different clinical scenarios. However, the level of evidence employed towards personalised treatment decisions is still moderate. Therefore, a joint task force was created by the European Association for Neurosurgical Societies (EANS) and the European Association of Neuro-Oncology (EANO) in order to provide interdisciplinary guidance on the extent of resection (EOR) in glioma surgery. This task force assessed the data on the EOR in gliomas, evaluated the level of evidence and composed recommendations. The EOR is determined routinely by postoperative magnetic resonance imaging (MRI). Since EOR may be associated with survival and may have an impact on epilepsy, neurocognition, quality of life, neurological status and also on planning of radiation and pharmacotherapy (evidence classes I-IV), recommendations of different levels can be made for the resection of newly diagnosed glioblastomas (level A), recurrent glioblastomas (level C), newly diagnosed (level B) and recurrent (good practice point) IDH mutant gliomas, ependymomas in children (level B) and adults (good practice point) as well as World Health Organization (WHO) CNS grade 1 tumors (good practice point). We hereby report the outcome of this collaborative effort by the joint task force between EANS and EANO.</p>","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":""},"PeriodicalIF":13.4,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145092228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PBTF Childhood and Adolescent Brain Tumor Facts.","authors":"","doi":"10.1093/neuonc/noaf214","DOIUrl":"10.1093/neuonc/noaf214","url":null,"abstract":"","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":"27 Supplement_1","pages":"NA"},"PeriodicalIF":13.4,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12448582/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145091928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EGFR/ZBED1 reciprocal regulation promotes stemness and tumorigenesis in glioblastoma.","authors":"Nana Hou, Yutao Wang, Qiuxiang You, Lei Zhang, Wenjia Zhang, Xinyi Wang, Chunyan Deng, Jiachuan Yan, Saiyu Cheng, Jianwen Ji, Jianbing Hou, Hongjuan Cui, Yundong Zhang","doi":"10.1093/neuonc/noaf215","DOIUrl":"https://doi.org/10.1093/neuonc/noaf215","url":null,"abstract":"<p><strong>Background: </strong>Glioblastoma stem cells (GSCs), a stem-like tumorigenic subpopulation within glioblastoma (GBM), exhibit remarkable self-renewal capacity and therapeutic resistance. Zinc finger BED domain-containing protein 1 (ZBED1), a dual-function transcription factor and SUMO E3 ligase, has been implicated in oncogenic processes across malignancies, its functional role and regulatory mechanisms in GSCs remain enigmatic.</p><p><strong>Methods: </strong>Multimodal approaches including immunohistochemistry, immunoblotting, and immunofluorescence were employed to evaluate ZBED1 expression patterns in GSCs and clinical GBM specimens. Functional characterization utilized in vitro models (proliferation assays, tumor-sphere formation assays, limiting dilution analysis) complemented by in vivo orthotopic xenograft models. Mechanistic investigations integrated RNA sequencing, label-free proteomics, chromatin immunoprecipitation (ChIP), immunohistochemistry, and western blotting to delineate the EGFR/ZBED1 regulatory axis.</p><p><strong>Results: </strong>We demonstrated that ZBED1 was significantly upregulated in GSCs and linked to unfavorable prognosis. Genetic ablation of ZBED1 significantly impaired GSC proliferation and self-renewal capacity, while extending survival in xenograft models. Mechanistically, EGFR-mediated ZBED1 phosphorylation at tyrosine residues Y160/Y513 enhanced ZBED1-UBC9 interaction, promoting SUMOylation-dependent protein stabilization. Remarkably, ZBED1 reciprocally sustained EGFR expression through transcriptional repression of the E3 ubiquitin ligase PARK2, establishing a self-reinforcing EGFR/ZBED1/PARK2 signaling circuit critical for GSC maintenance.</p><p><strong>Conclusions: </strong>Our findings elucidate a novel EGFR/ZBED1 positive feedback loop that drives GSC propagation and tumorigenesis, highlighting ZBED1 as an attractive candidate for therapeutic targeting in GBM.</p>","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":""},"PeriodicalIF":13.4,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145092250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Co-activation of super-enhancer complex SOX2 and HDAC1 confers temozolomide resistance by promoting PDGFB transcription in glioblastoma.","authors":"Han Xie, Tongjie Ji, Chunyu Zhang, Meng Cheng, Rui Wang, Yueyao Wu, Jingzhe Wang, Honghao Wang, Junyu Yang, Siyi Xu, Min Liu, Jing Zhang, Chunlong Zhong","doi":"10.1093/neuonc/noaf219","DOIUrl":"https://doi.org/10.1093/neuonc/noaf219","url":null,"abstract":"<p><strong>Background: </strong>Temozolomide (TMZ) resistance remains the major obstacle in the treatment of glioblastoma (GBM). We previously found that the super-enhancer (SE) complex is involved in the regulation of genes related to tumor biology, but its mechanisms in mediating TMZ resistance in GBM remain poorly characterized.</p><p><strong>Methods: </strong>Comprehensive in vitro and in vivo functional experiments were conducted using patient-derived cells (PDCs), patient-derived organoids, and PDCs xenograft models. Cleavage Under Targets and Tagmentation, chromatin immunoprecipitation, co-immunoprecipitation, mass spectrometry, protein fragment complementation assay, dual-luciferase reporter assay, fluorescence polarization assay, and surface plasmon resonance assay were employed to unravel the molecular mechanisms.</p><p><strong>Results: </strong>We found that SOX2 is significantly upregulated in TMZ-resistant PDCs and associated with the poor prognosis of recurrent GBM patients. Moreover, inhibition of SOX2 enhanced TMZ-induced apoptosis and DNA damage response, thereby promoting TMZ chemosensitivity. Mechanically, we identified PDGFB as a novel SE-associated oncogene mediated by SOX2. SE complex SOX2 and HDAC1 were recruited together to the SE region of PDGFB, synergistically triggering the PDGFB-MAPK/PI3K signaling axis and ultimately promoting TMZ resistance. Notably, virtual screening targeting the critical interaction domain between SOX2 and HDAC1 identified the FDA-approved drug fluvastatin as a potent SOX2 inhibitor that effectively sensitizes GBM cells to TMZ.</p><p><strong>Conclusions: </strong>Targeting the SE complex enhances TMZ chemosensitivity in GBM, providing a promising therapeutic avenue to overcome drug resistance and improve clinical outcomes.</p>","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":""},"PeriodicalIF":13.4,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145092226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2017-2021.","authors":"Mackenzie Price, Christine Ann Pittman Ballard, Julia R Benedetti, Carol Kruchko, Jill S Barnholtz-Sloan, Quinn T Ostrom","doi":"10.1093/neuonc/noaf168","DOIUrl":"10.1093/neuonc/noaf168","url":null,"abstract":"<p><p>This report comprehensively describes the most up-to-date incidence of primary brain and other central nervous system (CNS) tumors in children and adolescents (ages 0-19 years old), utilizing population-based data collected and reported by central cancer registries covering 99.9% of the United States population. Overall, brain and other CNS tumors are the most common cancer and the most common cause of cancer death in children and adolescents. This report aims to serve as a resource for researchers, clinicians, patients, and families.</p>","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":"27 Supplement_1","pages":"i1-i42"},"PeriodicalIF":13.4,"publicationDate":"2025-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12448625/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145092005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glioma-white matter tract interactions: A diffusion magnetic resonance imaging-based 3-tier classification and its clinical relevance.","authors":"Jie Hu, Hongbo Bao, Xing Liu, Shengyu Fang, Zeya Yan, Zihan Wang, Renwu Zhang, Ruiyang Wang, Tingting Pu, Chao Li, Zaixu Cui, Tao Jiang, Yinyan Wang","doi":"10.1093/neuonc/noaf036","DOIUrl":"10.1093/neuonc/noaf036","url":null,"abstract":"<p><strong>Background: </strong>This study proposed a classification system for the interaction between gliomas and white matter tracts, exploring its potential associations with clinical characteristics, tumor pathological subtypes, and patient outcomes.</p><p><strong>Methods: </strong>Clinical data and diffusion magnetic resonance imageing (dMRI) from 360 glioma patients who underwent craniotomy were analyzed. Using automatic fiber tractography, glioma-tract relationships were categorized into 3 types: displacement, infiltration, and disruption. Double immunohistochemical staining for isocitrate dehydrogenase (IDH) and myelin basic protein was performed on neuronavigation-guided tissue samples to validate the imaging-based classifications. The clinical implications of these classifications on the extent of tumor resection, postoperative motor function, and survival outcomes were evaluated.</p><p><strong>Results: </strong>Among the patients, 35 (9.7%) were categorized as displacement type, 283 (78.6%) as infiltration type, and 42 (11.7%) as disruption type. Disruption-type tracts were predominantly associated with IDH wild-type gliomas (87.2%), significantly higher than infiltration (28.5%) and displacement types (23.5%) (P < .001). Displacement and infiltration types were more common in IDH-mutant gliomas (P < .001). Displacement-type tracts were significantly associated with higher rates of gross tumor resection compared to infiltration types (P = .015). In corticospinal tract involved cases, displacement-type tumors demonstrated no significant postoperative motor strength changes, whereas infiltration (P < .001) and disruption types (P = .013) were highly associated with postoperative motor deficits. Histological results aligned with dMRI-based classifications.</p><p><strong>Conclusions: </strong>This dMRI-based classification of glioma-tract interactions is significantly associated with tumor pathology, resection outcomes, functional prognosis, and survival, providing a valuable tool for personalized and precise surgical planning.</p>","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":"1888-1898"},"PeriodicalIF":13.4,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12417821/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143408466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}